Skip to main content

Table 1 EGFR mutations detected in ctDNA of NSCLC patients

From: Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

Authors Case number Method Positive (%) Sensitivity (%) Specificity (%) Concordance (%)
Sun H [21] 55 MST-PCR 18.2 NM NM NM
Douillard JY [22] 784 ARMS 10.5 65.7 99.8 94.3
Kim HR [23] 40 PNA-PCR 15 17.1 100 27.5
Punnoose EA [37] 24 DxS kits 16.7 100 100 100
Goto K [40] 194 DxS Kits + ARMS 23.7 43 100 66.3
Jian G [81] 56 RT-PCR 23.2 NM NM NM
He C [38] 134 ME-PCR 49.3 100 90 94.4
Zhang L [82] 627 ME-PCR 22 NM NM NM
Zhao X [83] 111 ME-PCR + sequencing 17.1 35.6 95.5 71.2
Kimura H [39] 27 PCR + sequencing 37 75 71.4 NM
Kim ST [84] 57 PNA-LNA PCR 19.3 66.7 93.3 87.7
Bai H [85] 230 DHPLC 34.3 81.8 89.5 74
Yung TK [41] 35 Digital PCR 43 92 100 NM
Mack PC [42] 49 DxS kits 20.4 66.7 100 NM
Kuang Y [86] 54 ARMS 47 70 85 NM
Kimura H [87] 42 ARMS 16.7 75 97.1 92.9
Kimura H [88] 27 ARMS 48.1 50 85.7 72.7
Brevet M [89] 31 ME-PCR + sequencing 58.1 38.9 84.6 NM
Jiang B [43] 58 ME-PCR + sequencing 24.1 77.8 100 93.1
Wang S [90] 134 ARMS 12.7 22.1 97 59
Jing CW [91] 120 HRM 25.8 64.4 97.3 85
Zhang H [44] 86 MEL 17.4 68.2 100 91.9
Liu X [45] 86 ARMS 31.4 67.5 100 84.9
Xu F [46] 34 ARMS 11.8 50 100 88.2
Huang Z [92] 822 DHPLC 32.7 63.5 84.6 77
Sriram KB [47] 64 ME-PCR 4.7 50 100 95.3
Weber B [50] 196 cobas® EGFR test 11.7 60.7 96.4 91.3
  1. MST mutant-specific primers with a Taqman probe, PCR polymerase chain reaction, ARMS the amplification refractory mutation system, PNA-PCR peptide nucleic-acid-mediated PCR, DxS kits DxS EGFR Mutation Test Kit (DxS, Manchester, UK), RT-PCR real-time PCR, ME-PCR mutant-enriched PCR, PNA-LNA PCR the peptide nucleic-acid-locked nucleic acid PCR, DHPLC denaturing high-performance liquid chromatography, HRM high-resolution melting analysis, MEL mutant-enriched liquidchip, NM not mentioned